© The Financial Times Ltd 2014 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Mar 01, 2014, the consensus forecast amongst 3 polled investment analysts covering Cell Therapeutics Inc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 04, 2013. The previous consensus forecast advised investors to purchase equity in Cell Therapeutics Inc.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 3 analysts offering 12 month price targets for
Dividend information is not available for
On Mar 04, 2014,
|Average growth rate||-2.28 %|
|Average growth rate||+45.22 %|
Cell Therapeutics, Inc. had 4th quarter 2013 revenues of 520.00k. This missed the 1.26m consensus estimate of the 3 analysts following the company. This was 43.65% above the prior year's 4th quarter results. View Full Interim Financials
|Average growth rate||-3.63 %|
Cell Therapeutics, Inc. had revenues for the full year 2013 of 2.31m. View Full Annual Financials
|Average growth rate||+66.25 %|